Unified Protocol for Transdiagnostic Prevention of Depression and Anxiety in Iranian Adolescents: Protocol Development and Initial Outcome Data
AbstractObjective: Cognitive-behavioral interventions have been used as effective approaches for the treatment and prevention of depression and anxiety. However, to date, no anxiety and depression prevention guidelines package has been developed for Iranian adolescents. Thus, the purpose of this study was to develop transdiagnostic prevention program of anxiety and depression for Iranian adolescents and to assess the effectiveness of this program in a sample of adolescents. Method: Based on evidence-based literatures on CBT interventions, transdiagnostic prevention program was developed and its content and face validity was assessed and established by 3 clinical psychologies (Ph.D.) and a psychiatrist (child and adolescent postdoctoral). Then, in a semi-experimental design, 62 students were recruited from a school in Tehran by purposive sampling method and were randomly assigned in to experimental (n = 40) and control (n = 22) groups. They participated in 8 sessions of intervention based on the developed program. Revised Child Anxiety and Depression Scale (RCADS)- Child Version and Parent Version- were used to gather the data before, after, and 3 months after intervention. Results: Results of ANCOVA, controlling for the effect of pretest score, showed no significant differences (P>0.05) between experimental and control groups in SAD, panic, MDD, separation anxiety, GAD, OCD, total anxiety, and total anxiety-depression for parent and child in pretest and posttest. Conclusion: Transdiagnostic prevention package for anxiety and depression had no significant effect on reducing anxiety and depression of adolescents. Using an inappropriate measure, difficulties with timing of assessment, and lower severity of pre-intervention anxiety and depression due to universal prevention and sample recruited, might have affected the present findings. Discussion would be clearer and more complete by analyzing follow-up results and education performance in the future.
Table A. 3: burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002. The world health report. 2004.
Kessler RC, Sampson NA, Berglund P, Gruber M, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiology and psychiatric sciences. 2015;24(03):210-26.
Baxter A, Scott K, Vos T, Whiteford H. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychological Medicine. 2013;43(05):897-910.
Mohammadi M-R, Davidian H, Noorbala AA, Malekafzali H, Naghavi HR, Pouretemad HR, et al. An epidemiological survey of psychiatric disorders in Iran. Clinical practice and epidemiology in mental health. 2005;1(1):16.
Avenevoli S, Swendsen J, He J-P, Burstein M, Merikangas KR. Major depression in the National Comorbidity Survey–Adolescent Supplement: prevalence, correlates, and treatment. Journal of the American Academy of Child & Adolescent Psychiatry. 2015;54(1):37-44. e2.
Merikangas KR, He J-p, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry. 2010;49(10):980-9.
Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychological medicine. 2008;38(03):365-74.
Cummings CM, Caporino NE, Kendall PC. Comorbidity of anxiety and depression in children and adolescents: 20 years after. Psychological bulletin. 2014;140(3):816.
Zhiguo W, Yiru F. Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai archives of psychiatry. 2014;26(4):227.
Saveanu R, Etkin A, Duchemin A-M, Goldstein-Piekarski A, Gyurak A, Debattista C, et al. The International Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. Journal of psychiatric research. 2015;61:1-12.
Rapee RM, Lyneham HJ, Hudson JL, Kangas M, Wuthrich VM, Schniering CA. Effect of comorbidity on treatment of anxious children and adolescents: Results from a large, combined sample. Journal of the American Academy of Child & Adolescent Psychiatry. 2013;52(1):47-56.
Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Archives of general psychiatry. 2011;68(1):90-100.
Karlsson L, Pelkonen M, Ruuttu T, Kiviruusu O, Heilä H, Holi M, et al. Current comorbidity among consecutive adolescent psychiatric outpatients with DSM-IV mood disorders. European child & adolescent psychiatry. 2006;15(4):220.
Fichter M, Quadflieg N, Fischer UC, Kohlboeck G. Twenty‐five‐year course and outcome in anxiety and depression in the Upper Bavarian Longitudinal Community Study. Acta Psychiatrica Scandinavica. 2010;122(1):75-85.
Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. Journal of abnormal psychology. 2001;110(4):585.
Üstün T, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. The British journal of psychiatry. 2004;184(5):386-92.
Mathew A, Pettit J, Lewinsohn P, Seeley J, Roberts R. Co-morbidity between major depressive disorder and anxiety disorders: shared etiology or direct causation? Psychological medicine. 2011;41(10):2023-34.
Kessler RC, Greenberg PE. The economic burden of anxiety and stress disorders. Neuropsychopharmacology: The fifth generation of progress. 2002;67:982-92.
Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. Journal of abnormal psychology. 1991;100(3):316.
Watson D. Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V. Journal of abnormal psychology. 2005;114(4):522.
Allen LB, Tsao JC, Seidman LC, Ehrenreich-May J, Zeltzer LK. A unified, transdiagnostic treatment for adolescents with chronic pain and comorbid anxiety and depression. Cognitive and Behavioral Practice. 2012;19(1):56-67.
Chu BC. Translating transdiagnostic approaches to children and adolescents. Elsevier; 2012.
Klemanski DH, Curtiss J, McLaughlin KA, Nolen-Hoeksema S. Emotion Regulation and the Transdiagnostic Role of Repetitive Negative Thinking in Adolescents with Social Anxiety and Depression. Cognitive therapy and research. 2017;41(2):206-19.
Barrett P, Turner C. Prevention of anxiety symptoms in primary school children: Preliminary results from a universal school‐based trial. British Journal of Clinical Psychology. 2001;40(4):399-410.
Raes F, Griffith JW, Van der Gucht K, Williams JMG. School-based prevention and reduction of depression in adolescents: A cluster-randomized controlled trial of a mindfulness group program. Mindfulness. 2014;5(5):477-86.
Woidneck MR, Morrison KL, Twohig MP. Acceptance and commitment therapy for the treatment of posttraumatic stress among adolescents. Behavior Modification. 2014;38(4):451-76.
Swain J, Hancock K, Dixon A, Koo S, Bowman J. Acceptance and Commitment Therapy for anxious children and adolescents: study protocol for a randomized controlled trial. Trials. 2013;14(1):140.
Corrieri S, Heider D, Conrad I, Blume A, König H-H, Riedel-Heller SG. School-based prevention programs for depression and anxiety in adolescence: A systematic review. Health promotion international. 2013;29(3):427-41.
Fisak BJ, Richard D, Mann A. The prevention of child and adolescent anxiety: A meta-analytic review. Prevention Science. 2011;12(3):255-68.
Gladstone TR, Beardslee WR, O’Connor EE. The prevention of adolescent depression. Psychiatric Clinics of North America. 2011;34(1):35-52.
Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM, et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Archives of general psychiatry. 2007;64(6):651-60.
Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE. Assessment of symptoms of DSM-IV anxiety and depression in children: A revised child anxiety and depression scale. Behaviour research and therapy. 2000;38(8):835-55.
Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and Depression Scale in a clinical sample. Behaviour research and therapy. 2005;43(3):309-22.
Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. Jama. 2009;301(21):2215-24.
Beardslee WR, Brent DA, Weersing VR, Clarke GN, Porta G, Hollon SD, et al. Prevention of depression in at-risk adolescents: longer-term effects. JAMA psychiatry. 2013;70(11):1161-70.
Horowitz JL, Garber J. The prevention of depressive symptoms in children and adolescents: A meta-analytic review. American Psychological Association; 2006.
Barrett PM, Farrell LJ, Ollendick TH, Dadds M. Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends program. Journal of clinical child and adolescent psychology. 2006;35(3):403-11.
Clark DA, Taylor S. The transdiagnostic perspective on cognitive-behavioral therapy for anxiety and depression: new wine for old wineskins? Journal of Cognitive Psychotherapy. 2009;23(1):60-6.
Dozois DJ, Seeds PM, Collins KA. Transdiagnostic approaches to the prevention of depression and anxiety. Journal of Cognitive Psychotherapy. 2009;23(1):44-59.